We believe the clinical attributes of our rhCollagen will translate into benefits for patients, payors, and physicians, and will be adopted rapidly by the market once our product candidates receive regulatory approval. The improved biofunctionality of our products is intended to lead to faster recovery, better clinical outcomes, and reduced hospitalization time. Our in vivo studies have shown faster tissue remodeling, faster wound closure, and reduced scarring compared to competing products made from tissue derived collagen.
We currently have in house research and development projects related to tendon rupture and surgical wounds as well as other nondisclosure therapeutic solutions, and are actively seeking collaborators in these indications. We are also pursuing other platforms for our rhCollagen.
For further details please contact us.